Implantica AG (STU:8IM1)

Q2 2025 Implantica AG Earnings Call Transcript

Aug 14, 2025 / 01:00 PM GMT

Release Date Price: €6.45 (+0.78%)

Transcript

Key Points

Positve

Implantica AG (FRA:8IM1) has published extraordinary 5-year pivotal study results for its main product, RefluxStop, demonstrating superior treatment outcomes compared to existing methods.
The company is preparing for a US launch, with FDA inspections scheduled and production ramp-up underway, including the order of 10,000 devices.
Implantica AG (FRA:8IM1) maintains a strong financial position with €56 million in cash and short-term investments, and no interest-bearing debt.
The company has developed two platform technologies, including an eHealth platform that allows remote monitoring and treatment adjustments, potentially revolutionizing healthcare.
Implantica AG (FRA:8IM1) has a robust patent portfolio with over 1,000 patent cases, providing strong intellectual property protection for its innovations.

Negative

Net sales decreased by 22% compared to the same period last year, driven by a focus on enrolling patients into a randomized clinical study.
The company faces challenges in achieving reimbursement in Europe, with many hospitals operating without full payment for the device.
There is uncertainty regarding the timeline for FDA approval, with potential delays due to the review process and upcoming holidays.
The company has experienced a reduction in R&D spending by 54%, which may impact future innovation and product development.
Implantica AG (FRA:8IM1) is reliant on FDA approval for its US market entry, which is crucial for its growth strategy and financial performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMPsdba.ST - Implantica AG
Q2 2025 Implantica AG Earnings Call
Aug 14, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon everybody. My name is Peter Pochell, and it's of course the Q2 presentation we are doing today.

So For new listeners, which we seem to get quite a few lately.

I'm a surgeon, I'm the inventor of the device. We will talk mostly about today.

And I also once developed adjust gastic band and a very successful business around that and the funding that has generating plantica is coming from this gastic band business.

So our main product, Cornerstone product is reflexop and that's targeting a treatment field of 1 billion suffers and that's enormous, absolutely enormous.

And here you see the device mounted on the insertion tool, which you use for a keyhole surgery, you see the metal that to

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.